EMA/FDA analysis shows high degree of alignment in marketing application decisions between EU and US

EMA and the US Food and Drug Administration (FDA) are aligned in more than 90% of marketing authorization decisions for new medicines

This is the first analysis by EMA and the FDA that compares the agencies’ decisions related to marketing authorizations. It is one of the findings of a joint EMA/FDA analysis comparing decisions on 107 new medicine applications at the two agencies between 2014 and 2016. The study also looked at applications for which the agencies had differing outcomes in terms of type of approval and indication. The most common reason for diverging decisions at the two agencies were differences in conclusions about efficacy. Differences in clinical data submitted in support of an application were the second most common root of divergent FDA and EMA decisions.

Read more online
Copyright Widler & Schiemann AG 2020. All Rights Reserved. /